Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
aTyr PharmaATYR +2.61%18 Equity-to-Asset is 0.73 as of Mar. 2026, which is 4% below its 10-year median of 0.76. GuruFocus rates ATYR with a GF Score™ of 18/100 and a GF Value™ of $0.45 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, aTyr Pharma ranks better than 56.14% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. aTyr Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $57.93 Mil. aTyr Pharma's Total Assets for the quarter that ended in Mar. 2026 was $79.65 Mil.
The historical rank and industry rank for aTyr Pharma's Equity-to-Asset or its related term are showing as below:
ATYR'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59 Med: 0.76 Max: 0.95
Current: 0.73
During the past 13 years, the highest Equity to Asset Ratio of aTyr Pharma was 0.95. The lowest was 0.59. And the median was 0.76.
ATYR's Equity-to-Asset is ranked better than 56.14% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs ATYR: 0.73
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
aTyr Pharma Equity-to-Asset Related Terms
aTyr Pharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for aTyr Pharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATYR vs IBO, BYSI, MCRB: Equity-to-Asset Comparison
For the Biotechnology subindustry, aTyr Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
aTyr Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (ATYR) has a Equity-to-Asset of 0.73 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on aTyr Pharma and its competitors. This is near median its historical median of 0.76. Over the past decade, aTyr Pharma's Equity-to-Asset has ranged from 0.59 to 0.95. According to the industry distribution chart, aTyr Pharma ranks #621 out of 1416 companies in the Biotechnology industry, placing it in the top 43.9%.
Is aTyr Pharma's Equity-to-Asset too high?
aTyr Pharma's current Equity-to-Asset of 0.73 is near median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 0.95. The Biotechnology industry median Equity-to-Asset is 0.68. aTyr Pharma's value of 0.73 is 7.4% above this industry median. Based on the distribution chart, aTyr Pharma ranks #621 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, aTyr Pharma has a GF Score™ of 18/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's Equity-to-Asset compare to IBO and BYSI?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #621 out of 1416 companies for Equity-to-Asset. This puts aTyr Pharma in the upper half of its industry. The industry median Equity-to-Asset is 0.68. aTyr Pharma's value of 0.73 is 7.4% above this benchmark. Historically, aTyr Pharma's own Equity-to-Asset has ranged from 0.59 to 0.95 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 0.68, aTyr Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. aTyr Pharma's current Equity-to-Asset of 0.73 is 7.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on aTyr Pharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. aTyr Pharma's current Equity-to-Asset is 0.73, which is near median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $0.51 — trading 13.6% above its estimated fair value. The current Equity-to-Asset is 0.73, which is near median its 10-year median of 0.76 and 7.4% above the Biotechnology industry median of 0.68. aTyr Pharma's overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current Equity-to-Asset is 0.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.51 is trading 13.6% above its estimated GF Value™ of $0.45.
GuruFocus considers aTyr Pharma to be Modestly Overvalued.
Key valuation signals for ATYR:
Equity-to-Asset: 0.73 (near median its 10-year median of 0.76)
GF Value™: $0.45 vs. price of $0.51 (13.6% above fair value)
Industry Position: 7.4% above the Biotechnology median (#621 of 1416)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
18GF Score
Get the complete analysis for ATYR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
